Procyon Technologies was pleased to see the efficacy and viability of the iPSC-derived MSCs over 12 weeks while encapsulated in our proprietary immunoisolation devices. For more information, see https://www.biorxiv.org/search/10.1101%252F2025.04.01.646502.
Cynata has just announced positive efficacy data from preclinical studies using our Cymerus™ iPSC-derived MSCs in ischaemic heart disease models.
Key highlights:
– Significantly improved heart function and reduced harmful structural changes
– Extended cell viability (12+ weeks) using a novel encapsulation device
– Successful minimally invasive delivery method
This represents a potential breakthrough in addressing the world’s leading cause of death, with promising implications for post-heart attack care where current treatments fail to adequately repair damaged heart tissue.
The project was supported by a ~$1M Australian Government Medical Research Future Fund grant and led by Associate Professor Shiang Lim (Max) of St Vincent’s Institute of Medical Research.